/Assessing And Treating Acute Decompensated Heart Failure
Abstract

This document provides methods and materials involved in assessing mammals with acute decompensated heart failure (ADHF), as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of plasma CNP and the level of urinary CNP to determine whether or not a mammal is developing or likely to develop more severe ADHF, as well as methods and materials for using the level of plasma CNP and the level of urinary CNP to identify patients having an increased likelihood of experiencing a poor outcome are provided.

Full Text

What is claimed is:

This document provides methods and materials involved in assessing mammals with acute decompensated heart failure (ADHF), as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of plasma CNP and the level of urinary CNP to determine whether or not a mammal is developing or likely to develop more severe ADHF, as well as methods and materials for using the level of plasma CNP and the level of urinary CNP to identify patients having an increased likelihood of experiencing a poor outcome are provided.
Timeline
Filed
05/27/2026
Published
09/17/2026
Granted
Not Available
IPC Codes(3)
A61K 38/22:Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin e.g. corticotropin A61K 38/33, A61K 38/35)
A61P 43/00:Drugs for specific purposes, not provided for in groups
G01N 33/68:involving proteins, peptides or amino acids